Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
424studies shown
Showing 157-168 of 424
Device study icon
RecruitingNCT07176468

Personalized iTBS in Real-World Clinical Settings for Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Hefei
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
China
Sponsor
Anhui Medical University
Condition
Schizophrenia
Behavioral study icon
RecruitingNCT07460453

Racial Disparities in the Expression of Paranoia

This summary needs review. Please check the official study record and contact the research team for details.

In Bloomington
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralOver 18 Years
Countries
United States
Sponsor
Indiana University
Condition
Schizophrenia
Drug study icon
RecruitingNCT06961968

Withdrawal Study in people with Schizophrenia

The registry lists this study as recruiting. Study locations are listed in the United States.

Multiple locations, including Rogers
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
United States
Sponsor
Vanda Pharmaceuticals
Condition
Schizophrenia
Device study icon
RecruitingNCT05956951

Restoring Spindle and Thalamocortical Efficiency in Early-Course Schizophrenia Patients Using Auditory Stimulation

This summary needs review. Please check the official study record and contact the research team for details.

In Pittsburgh
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDeviceA study involving a tool, app, wearable, test, or medical device.From 18 Years to 40 Years
Countries
United States
Sponsor
Fabio Ferrarelli
Condition
Schizophrenia
Behavioral study icon
RecruitingNCT05184335

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Phoenix
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralFrom 18 Years to 65 Years
Countries
United States
Sponsor
Reviva Pharmaceuticals
Condition
Schizophrenia
Behavioral study icon
RecruitingNCT06361407

Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Marseille
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralFrom 18 Years to 60 Years
Countries
France
Sponsor
Centre Psychothérapique de Nancy
Condition
Schizophrenia
Drug study icon
RecruitingNCT07122895

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Taichung
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 20 Years to 65 Years
Countries
Taiwan
Sponsor
China Medical University Hospital
Condition
Schizophrenia
Other study type icon
RecruitingNCT07419321

Social Isolation and Aging in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Hartford
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaObservationalA study where researchers collect information without assigning a treatment.From 40 Years to 70 Years
Countries
United States, United Kingdom, Netherlands, ...
Sponsor
Icahn School of Medicine at Mount Sinai
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.